Who are Pf-07832837's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Plegisol In Plastic Container, Plegisol In Plastic Container, C. difficile vaccine formulation 1., deep block, Met097, BNT162b2 vaccine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pf-07832837.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Pf-07832837 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pf-07832837 (pf-07832837) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Small molecule. Area: Other.

marketed Small molecule Not specified Other Live · refreshed every 30 min

Target snapshot

Pf-07832837 (pf-07832837) — Pfizer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pf-07832837 TARGET	pf-07832837	Pfizer	marketed	Small molecule	Not specified
Plegisol In Plastic Container	Sodium Chloride	Baxter	marketed	Electrolyte solution	Not specified	1965-01-01
Plegisol In Plastic Container	Sodium Chloride	Baxter	marketed	Electrolyte solution	Not specified	1965-01-01
C. difficile vaccine formulation 1.	c-difficile-vaccine-formulation-1	Pfizer Inc.	marketed	Vaccine	Not specified
deep block	deep block	Seoul National University Bundang Hospital	marketed	The drug class of deep block is not clearly defined.	The specific target or pathway that deep block aims to modulate is not specified.
Met097	met097	Pfizer	marketed	Not specified	Not specified
BNT162b2 vaccine	BNT162b2 vaccine	Vaxxinity, Inc.	marketed	Not specified	Not specified

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Small molecule class)

Pfizer · 3 drugs in this class
Akorn, Inc. · 1 drug in this class
Guangdong Hengrui Pharmaceutical Co., Ltd · 1 drug in this class
Health Research, Inc. · 1 drug in this class
Imperial College London · 1 drug in this class
Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
Nanjing Sanhome Pharmaceutical, Co., Ltd. · 1 drug in this class
Second Affiliated Hospital of Wenzhou Medical University · 1 drug in this class
UroGen Pharma Ltd. · 1 drug in this class
Abivax S.A. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pf-07832837 — Competitive Intelligence Brief. https://druglandscape.com/ci/pf-07832837. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing